Login
Register
Complete Your Profile
Change Password
Request a Password Reset
Download Documents
Download Documents
Get Help to Participate in This Tender
Change Password
For better security, update the account password.
Title/Summary: Tender for the supply of medicinal products belonging to ATC group L04AC21 with the active ingredient BIMEKIZUMAB, issued by Nemocnice Pardubického kraje, a.s. in Pardubice, Czech Republic. The contract duration is 4 years, with an estimated value of 23,120,298 CZK.
Scope Of Work: The scope involves the continuous supply of medicinal products classified under ATC group L04AC21 containing the active ingredient BIMEKIZUMAB for a duration of 4 years. The deliveries are to be made to Nemocnice Pardubického kraje, a.s., located at Kyjevská 44, Pardubice, Czech Republic.
Qualification Criterion: Bidders must meet eligibility criteria set forth by Nemocnice Pardubického kraje, a.s. This includes relevant experience in supplying medicinal products, compliance with applicable health regulations, and the ability to fulfill the contract terms over the specified duration. Mandatory submissions include proof of registration and compliance with Czech healthcare standards.
Purchaser contact is for registered users
Login to see detailsTender details are for registered users
Login to see details| Tender | Country | TOT Ref. No. | Bid deadline |
|---|---|---|---|
| Medicinal Product of Atc Group J06ba02 with the Active Substance Immunoglobulins, Normal Human, for Intravascular Application | Czech Republic | 152654081 | 18 Dec 2026 |
| Skiagraphic X-Ray Equipment Including Full Service Provision | Czech Republic | 152653770 | 15 Dec 2026 |
| Medicinal Product of Atc Group N02cd07 with the Active Substance Atogepant | Czech Republic | 152653358 | 18 Dec 2026 |
| Medicinal Product of Atc Group L04ac24 with the Active Substance Mirikizumab | Czech Republic | 152647180 | 18 Dec 2026 |
| Medicinal Product of Atc Group L03ab13 with the Active Ingredient Peginterferon Beta-1A | Czech Republic | 152644383 | 18 Dec 2026 |